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Abstract
The discovery of novel mucosal adjuvants will help to develop new formulations to control infectious and allergic
diseases. In this work we demonstrate that U-Omp16 from Brucella spp. delivered by the nasal route (i.n.) induced an
inflammatory immune response in bronchoalveolar lavage (BAL) and lung tissues. Nasal co-administration of U-
Omp16 with the model antigen (Ag) ovalbumin (OVA) increased the amount of Ag in lung tissues and induced OVA-
specific systemic IgG and T helper (Th) 1 immune responses. The usefulness of U-Omp16 was also assessed in a
mouse model of food allergy. U-Omp16 i.n. administration during sensitization ameliorated the hypersensitivity
responses of sensitized mice upon oral exposure to Cow’s Milk Protein (CMP), decreased clinical signs, reduced
anti-CMP IgE serum antibodies and modulated the Th2 response in favor of Th1 immunity. Thus, U-Omp16 could be
used as a broad Th1 mucosal adjuvant for different Ag formulations.
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Introduction
The main function of the mucosa is to maintain normal
physiology while discriminating between dangerous and
innocuous proteins or organisms [1]. Thus the induction of
mucosal immune responses is of paramount importance in
both health and disease.
Vaccination through the mucosal route is an interesting
strategy for antigen (Ag) administration because it is not
associated with pain or stress, and its administration is very
easy and cost-efficient. Induction of immune responses
following mucosal immunization -using non-live vaccines-is
usually dependent upon the co-administration of appropriate
adjuvants that can initiate and support the transition from
innate to adaptive immunity [2].
An adjuvant is a vaccine component that, through its
capacity to act as an immunomodulator/immunostimulant
induces and/or enhances an immune response against co-
delivered Ags. While there are many types of adjuvants, not all
of them are effective at promoting mucosal immune responses.
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In fact, alum, the most common adjuvant used in current
human vaccines, is a poor inducer of mucosal immunity.
Possibly the most studied mucosal adjuvants are the bacterial
derived ADP-ribosylating enterotoxins, including cholera toxin
(CT), heat-labile enterotoxin from Escherichia coli (LT), and
their mutants or subunits [3]. These enterotoxins promote the
induction of antigen-specific IgA antibodies and long-term
memory against co-administered antigens when delivered by
mucosal or transcutaneous route [2]. However, safety issues
have prevented full realization of the potential of this type of
mucosal adjuvants. Intranasal (i.n.) immunization, even with
low-toxicity mutants, can induce Bell’s palsy [4] and oral
administration with these toxin mutants induce poor
immunogenicity, as with the B-subunit alone. Therefore, at
present much work is being directed towards the development
of new low toxicity toxin derivates.
Another type of mucosal adjuvants are Toll-like receptor
(TLR) agonists [5]. These ligands activate these pathogen
recognition receptors, promoting intracellular signaling,
cytokine release and immune cell activation. Recently,
monophosphoryl lipid A was the first TLR agonist used in a
human vaccine formulation: the FDA approved human
papillomavirus vaccine, CervarixTM, by GlaxoSmithKline [6–8].
As the complex nature of mucosal immune induction is
understood promising new mucosal adjuvants can be
discovered [1]. A high-quality adjuvant would be of relevance
not only in vaccines against infectious diseases but also for the
control of allergic diseases. Currently, allergic diseases
represent a major health problem in industrialized countries. A
common feature of these diseases is the production of
allergen-specific IgE against normally innocuous food and
environmental Ags. Therefore, the majority of new interventions
try to control the overexpression of Th2 cytokines or skew the
Th1: Th2 balance towards a Th1 profile [9,10]. Unfortunately,
although many treatments for allergic diseases and anti-IgE
antibody therapies exist, these require a long term recurrent
administration of drugs [11].
Milk allergy is one of the most common food allergies with a
prevalence of 2.5% among children and 0.3% in adults [12].
There are different classifications of milk allergies: IgE-
mediated and non-IgE-mediated disorders [13]. Non-IgE-
mediated milk allergy is generally not considered life-
threatening, while IgE-mediated milk allergy has been
implicated in anaphylactic episodes, being milk the third most
common food responsible for severe food-induced anaphylactic
reactions in young children (8%-15% cases) [14,15]. The IgE-
mediated milk allergy involves production of IgE antibodies
upon first exposure to milk protein leading to sensitization of
mast cells. Subsequent exposures to the same milk Ags result
in a crosslinking of mast cells bound-IgE, leading to activation
and release of inflammatory mediators.
Previously, we reported that unlipidated outer membrane
protein of 16 kDa from B. abortus (U-Omp16) is a new Brucella
pathogen associated molecular pattern (PAMP) that activates
dendritic cell (DCs) in vivo and has self-adjuvanting properties
when administered by the oral or intraperitoneal route [16].
Taking into account these previous results, we hypothesized
that U-Omp16 would be a useful adjuvant in mucosal vaccine
formulations. In this work we studied the mucosal adjuvant
capacity of the protein U-Omp16 when is co-administered with
a model Ag (OVA) by the nasal route and also assessed its
capacity to modulate milk allergy in mice.
Results
U-Omp16 induces inflammatory cell recruitment to
bronchoalveolar lavage (BAL) and Ag internalization
Inflammatory cells initiate and drive adaptive immune
responses. To determine if U-Omp16 possesses the capacity
to recruit immune cells, mice were administered through the i.n.
route with U-Omp16 or PBS alone as control. BAL was
obtained at 12, 24 and 48 h following administration and total
cells were counted. U-Omp16 induced a significant increase in
the total cell number recruited to the BAL at 12 h (6.9x106 cells,
P<0.01 vs PBS group) (Figure 1A). However at 24 and 48 h
post administration there were no significant differences in the
number of total cells between U-Omp16 and PBS immunized
groups. We then studied the recruitment of macrophages,
neutrophils and lymphocytes to BAL after nasal delivery of U-
Omp16 or PBS as control. As shown in Figure 1B, nasal
administration of U-Omp16 induced the recruitment of
macrophages at 12 h post delivery in comparison with PBS
administered group. A slight but non-statistically significant
increase in neutrophils at 6 and 12 h and in lymphocyte
number at 12 h post delivery was observed in BAL from U-
Omp16 administered mice (Figure 1C and D).
Some adjuvants function by increasing the Ag’s half-life or
directing and increasing Ag internalization. This prompted us to
examine if U-Omp16 was able to increase the delivery of the
Ag in lungs after i.n. administration. Ag fate was studied using
ovoalbumin (OVA) conjugated with a fluorescent dye –Alexa
Fluor 647-, thus fluorescence intensity is proportional to the
amount of internalized Ag. To this end, animals were i.n.
administered with PBS, OVA(AF647) alone or OVA(AF647) plus U-
Omp16. Two, 12 and 24 hours after administration, lung tissue
cells were obtained from every animal and fluorescence
intensity was determined in a fluorescence plate reader. We
observed a rise in fluorescence intensity in lung cells derived
from animals immunized with OVA(AF647)+U-Omp16 in
comparison with mice immunized with OVA(AF647) alone (Figure
1E). Altogether these results indicate that U-Omp16 induces
the recruitment of inflammatory cells 12 h after nasal
administration and increases the amount of Ag inside lung
cells.
U-Omp16 induces the production of cytokines and
chemokines in BAL and lungs
To study the innate immune response induced by nasal
delivery of U-Omp16, we measured the level of pro- and anti-
inflammatory cytokines and chemokines involved in the
recruitment of different cell subtypes (monocytes, neutrophils
and lymphocytes). To this end, animals were i.n. administered
with U-Omp16 or PBS as negative control and at different time
points after administration mice were euthanized. Then TNF-α,
IL-10, CCL2, CCL3 and CCL5 production were determined in
BAL by ELISA. TNF-α and IL-10 production were also
measured in lung tissues. As observed in Figure 1, nasal
U-Omp16 Is a Th1 Mucosal Adjuvant
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administration of U-Omp16 induced a significant increase in the
production of TNF-α and IL-10 (P<0.001 and P<0.05 vs PBS
group) in lung tissues 24 h post delivery (Figure 1F). Besides, a
slight but non-statistically significant increase in the production
of TNF-αand IL-10 was observed at 12 h post U-Omp16 i.n
delivery in BAL. In agreement with the non-significant
Figure 1.  Inflammatory response induced after nasal delivery of U-Omp16.  C57BL/6 mice (n=5/group) were intranasally
administered with U-Omp16 or PBS as control and the number of total cells (A) and differential counts of macrophages (B),
neutrophils (C) and lymphocytes (D) were determined in BAL at different time points. (E) Animals were intranasally administered
with OVA(AF647) alone or OVA(AF647) plus U-Omp16. Lungs were obtained at different time points after delivery and the emission of
fluorescence was evaluated in cell suspensions from each lung (1 x106 cells). (F) C57BL/6 animals were administered through the
nasal route with U-Omp16 or PBS as control and at different times post administration the level of TNF-α, IL-10 in lung tissues, and
(G) TNF-α, IL-10, CCL2, CCL3 and CCL5 in BAL were determined by ELISA. Samples were assayed in duplicated and data
represent the mean ±SEM from each group of five mice, (**P<0.001, *P<0.05 vs PBS group). These results are representative of 3
independent experiments with similar results.
doi: 10.1371/journal.pone.0069438.g001
U-Omp16 Is a Th1 Mucosal Adjuvant
PLOS ONE | www.plosone.org 3 July 2013 | Volume 8 | Issue 7 | e69438
recruitment of neutrophils the amount of KC and
myeloperoxidase did not significantly increase in BAL from U-
Omp16 administered mice (data not shown). Besides, U-
Omp16 induced the production of pro-inflammatory
chemokines CCL2, CCL3 at 12 and 24 h post delivery in BAL
while CCL5 at 6 and 12 h (P<0.05 vs PBS group) (Figure 1G).
These results indicate that U-Omp16 stimulates the production
of pro-inflammatory cytokines (TNF-α) and chemokines (CCL2,
CCL3 and CCL5) and anti-inflammatory cytokines (IL-10) at the
lung.
U-Omp16 co-administered with OVA through the nasal
route induces a Th1 immune response
Next we investigated if nasal co-delivery of U-Omp16 with
the model Ag OVA would promote adaptive immune
responses. For this, mice were i.n. immunized with OVA plus i)
PBS, ii) U-Omp16 or iii) U-Omp16 completely digested with
proteinase K. Three weeks post vaccination animals were
sacrificed, spleen cells were obtained and cultured with OVA or
complete medium.
Upon stimulation with OVA, splenocytes from U-
Omp16+OVA-immunized mice showed a significant production
of IFN-γ (P<0.05 vs OVA or U-Omp16+PK groups).
Splenocytes from animals immunized with U-Omp16 previously
digested with proteinase K plus OVA induced similar levels of
IFN-γ production upon Ag stimulation to OVA immunized group
(Figure 2A). These results indicate that U-Omp16’s adjuvant
capacity resides in the protein moiety and is not due to any
other non-protein contaminant present in the U-Omp16´s
preparation. There were no significant differences in IL-17, IL-4
nor IL-10 secretion upon Ag stimulation between all the
immunized groups (Figure 2B–D). Taken together, these
results indicate that U-Omp16 used as a nasal adjuvant drives
the immune response towards a Th1 profile.
To expand upon these findings we decided to investigate
which cells are the sources of IFN-γ upon Ag stimulation.
Hence, splenocytes and lung cells from immunized animals
were obtained and stimulated or not with OVA. Nasal co-
delivery of U-Omp16 as adjuvant induced an increase in the
frequency of CD8+- and CD4+- IFN-γ-producing T cells (1.23%
and 0.89%, respectively) in spleens (Figure 2E) while an
increase in IFN-γ producing CD8+ T cells (2.32%) at lungs
(Figure 2F) upon OVA stimulation. When CT has been used as
nasal adjuvant with OVA, there was no increase in the
frequency of spleens or lungs IFN-γ producing T cells upon Ag-
stimulation (Figure 2E and F). Additionally, the humoral
immune response was evaluated measuring OVA-specific IgG
levels in serum from immunized mice. Co-administration of U-
Omp16 with OVA increased OVA-specific IgG in comparison to
animals vaccinated with OVA alone or with OVA plus U-
Omp16+PK (Figure 2G). U-Omp16 as nasal adjuvant induced
anti-OVA IgG1 and IgG2a serum antibodies with a slight bias
on IgG1 versus IgG2a secretion (IgG1/IgG2a ratio=2) (Figure
2G). Of note, U-Omp16 nasal co-delivery with OVA did not
induce serum IgG responses against U-Omp16 (the adjuvant)
(Figure 2H).
Overall, these results demonstrate that the administration of
U-Omp16 as nasal adjuvant with OVA, as model Ag, induces
Ag-specific Th1 immune responses with systemic Ag-specific
IgG production. IFN-γ production is mediated by CD4+ and
CD8+ T cells systemically (spleens), and by CD8+ T cells at the
mucosal site (lungs).
U-Omp16 does not induce a pathological immune
response at the lung or CNS after administration or
vaccination
To evaluate the safety profile of U-Omp16 at the lung and
CNS different experiments were conducted. Histological
sections of lungs and brains from immunized mice were
obtained, stained with H&E and evaluated by a pathologist. In
coincidence with the recruitment results showed in Figure 1, a
transient infiltration of immune cells in perivascular region at 12
h post U-Omp16 (Figure S1A) or U-Omp16+OVA (Figure S1C)
nasal delivery was observed at the lung, while tissue
morphology was not affected with any pathological changes
induced. At 24 h post U-Omp16+OVA nasal delivery the
infiltration diminished remaining similar to OVA-delivered group
(Figure S1D). At 2 weeks post nasal U-Omp16 delivery no
cellular infiltrate was observed and the lung showed complete
resolution of the inflammation with no apparent infiltration or
edema as in the control with PBS (Figure S1B). Lung histology
was also studied after a second i.n administration of U-Omp16
(2 weeks after 2 doses of U-Omp16+OVA) and there was no
alteration of the lung tissue architecture, thus indicating that no
pathological adverse reaction is promoted even in the presence
of a memory immune response (Figure S1E). In contrast, CT
co-administration induced a prominent infiltration with vessel
congestion, edema, microhaemorrhage foci and thickened
septums (Figure S1C-D). Therefore, we conclude that U-
Omp16 produce no lung remodeling with a transient
inflammation followed by a spontaneous recovery of the tissue
architecture. Moreover, no inflammatory reaction was observed
at the olfactory bulb neither after U-Omp16 nasal
administration (12 h and 2 weeks after) nor after U-
Omp16+OVA nasal immunization (2 weeks after 2 doses)
(Figure S2E).
We also studied if OVA or U-Omp16 can reach CNS
(olfactory bulb, forebrain and posterior brain) after nasal
administration of OVA+U-Omp16 at different time points after
delivery (2, 12 and 24 h). Different experimental methods were
used to assess the presence of antigen and adjuvant in CNS
tissues after the nasal delivery: i) by Western Blot with an anti-
OVA antibody or with U-Omp16-specific antiserum and ii)
fluorescence quantification (using FITC-labeled OVA). Neither
OVA nor U-Omp16 in the different samples analyzed was
detected (Figure S2A–D) indicating that after nasal delivery no
vaccine component reached the CNS.
U-Omp16 reduces the symptoms in a food allergy
mouse model
To confront our results obtained with OVA with a relevant
food allergen and to study its potential application in allergy
vaccines, we evaluated the U-Omp16’s adjuvant capacity to
prevent the induction of a specific allergic reaction in a mouse
model of food allergy. To conduct these experiments, mice
were sensitized by gavage with Cow’s Milk Protein (CMP) +CT
while simultaneously administered i.n with CMP alone or with
U-Omp16 Is a Th1 Mucosal Adjuvant
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LPS plus CMP as treatment control, or with U-Omp16 plus
CMP. In Figure 3A a schematic representation of the
sensitization schedule is depicted. The clinical signs recorded
following the oral challenge were scored and are shown in
Figure 3B. Animals treated i.n. during sensitization with CMP
alone showed a higher score level as compared to treated mice
with CMP and adjuvants. The use of LPS or U-Omp16 with the
co-administered Ag rendered lower scores (average score 1.5
Figure 2.  U-Omp16 induces a T helper 1 immune response when administered as nasal adjuvant.  C57BL/6 mice were
immunized by the nasal route with: OVA plus (i) PBS or ii) U-Omp16 previously digested with proteinase K (U-Omp16PK) or plus
(iii) U-Omp16. Three weeks after last immunization animals were sacrificed and spleen cells were stimulated in vitro with OVA 500
µg/ml or complete medium (RPMI). Culture supernatants were harvested 5 days after stimulation and cytokine concentration of (A)
IFN-γ, (B) IL-17, (C) IL-4 and (D) IL-10 (pg/ml) were determined by ELISA. U-Omp16 when administered as nasal adjuvant
stimulates the induction of CD4+ and CD8+ OVA-specific T cells that produce IFN-γ. Percentages are represented for spleen (E)
CD8+ or CD4+ T lymphocytes, and lung CD8+ T cells (F) expressing IFN-γ. (G) Anti-OVA IgG was determined in sera from
immunized animals on days 0 (pre-immune) and 30 (post-immune) by indirect ELISA. Data represent the mean ±SEM from each
group of five mice; (***P<0.001, **P<0.01, *P<0.05 vs OVA group). These results are representative of 3 independent experiments
with similar results.
doi: 10.1371/journal.pone.0069438.g002
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for Treat LPS, 1.55 for Treat OMP 16 and 3.1 for Treat CMP)
indicating that the use of U-Omp16 ameliorates the
hypersensitivity responses of sensitized mice upon oral
exposure to Ag.
We next addressed the ability of the different treatments to
prime a Delayed-type hypersensitivity (DTH) response, as a
reflection of the CD4+ T cell ability to induce a Th1-mediated
immunomodulation. As shown in Figure 3C a higher DTH
response was observed in mice that received U-Omp16 or LPS
as adjuvant, as compared to that in sensitized mice that
received CMP alone as treatment. Saline injected in the
contralateral hint footpad rendered a negligible swelling. The
average scores for each group were U-Omp16= 0.21mm,
LPS= 0.17mm and CMP= 0.08mm.
To investigate if this suppressed reaction could be linked to a
milder allergy the presence of IgE bound to skin mast cells was
assessed by cutaneous tests. Figure 3D shows the results of
the skin challenge with CMP, and as it can be seen, an
immediate extravasation of the blue dye was only achieved in
sensitized mice treated with CMP in vehicle. No increase in
vascular permeability was observed in mice treated with U-
Omp16 or LPS.
Overall, these results indicate that U-Omp16 modulates the
CMP-specific allergic immune response in vivo, preventing the
clinical reaction against oral exposure to the Ag.
Intranasal immunization with U-Omp16 promotes a
decrease in the IgE antibody response and an increase
in the IgG2a level
To investigate if U-Omp16 promotes a specific Th1-mediated
immune response that modulates the allergic state we
evaluated the immunoglobulin isotypes by immunoassays.
Figure 3E shows the kinetics of induction of CMP-specific
IgG1, IgG2a and IgE immunoglobulins. During the sensitization
phase CMP-specific IgE and IgG1 were induced, which reflects
that a Th2-immune response is triggered against CMP with the
use of CT through the oral route. In contrast, when U-Omp16
plus CMP was administered, specific CMP IgG2a antibodies
were induced, whereas IgG1 remained unchanged, and
remarkably, IgE was down-modulated. As expected, LPS
administration induced an increase in both IgG1 and IgG2a in
comparison with the control treatment group. The IgG1/IgG2a
ratio, which indicates whether a Th1 or a Th2 type immune
response prevails, suggested that U-Omp16 induced in vivo a
bias towards a Th1 immune profile.
U-Omp16 promotes spleen CD4+ T cells to produce IFN-
γ upon CMP stimulation and imprints a mucosal Th1
immune profile
To confirm that U-Omp16 treatment was able to induce a
CMP-specific Th1 response we investigated the cytokine
production of splenocytes and mRNA expression in jejunum
from mice treated through the nasal route. Co-administration of
CMP with U-Omp16 or LPS induced an increase in the
frequency of CMP-specific IFN-γ producing CD4+ T cells while
reduced IL-5 secretion by spleen cells compared to CMP
treated-mice (Figure 3F and G), indicating the Th1-shifted
immune response.
To further characterize the response induced in the gut
mucosa after U-Omp16 nasal treatment, gata-3 and t-bet gene
expression in jejunum of treated mice were determined. As
shown in Figure 3H U-Omp16 modulated the ifn-γ and il-5
gene expression in jejunum of mice treated with this adjuvant,
as compared to mice that received only CMP as treatment.
Furthermore, a local increased t-bet gene expression that fitted
with the Th1-biased immune response induced was evidenced.
In contrast, gata-3 expression remained similar to CMP treated
animals.
Cholera Toxin plus CMP administration induces a mild
inflammation in the gut mucosa with a mononuclear infiltrate.
There were no significant differences in the cellular
composition of the gut mucosa between the groups (data not
shown).
Overall these results provide strong evidence indicating that
U-Omp16 administered at a distant mucosal site is a Th1
immune inducer that can modulate the Th2-mediated allergic
sensitization.
Discussion
Given their potent immunostimulatory capacity, bacterial-
derived substances constitute a major potential source of
adjuvants. In a previous work we discovered that U-Omp16
from Brucella is a new PAMP that signals through TLR4 and
has self-adjuvanting properties when delivered either
parenterally or orally [16].
In this work we demonstrate that nasal co-delivery of Ag with
U-Omp16 induces Ag-specific Th1 responses at systemic
(spleen) and mucosal (lungs and gut) levels. Also, U-Omp16
improved systemic humoral immune. The IFN-γ production
induced with OVA administration is mediated by CD4+ as well
as CD8+ T cells. The adjuvant capacity could not be due to LPS
contamination, since U-Omp16 preparations were exhaustedly
depleted of LPS with polymyxin B sepharose, as assessed by
LAL assay. Moreover, U-Omp16 lost its Th1 adjuvant capacity
when it was completely digested with proteinase K, indicating
that the in vivo properties of U-Omp16 are in fact due to this
protein rather than to another non-protein contaminant. In
addition, there were no OVA-specific Th2 responses after U-
Omp16 nasal delivery. It has been reported that i.n.
immunization leads per se to Th17-biased immune responses,
regardless of the adjuvant used [17]. However, in this work, we
did not find in vitro IL-17 release from stimulated splenocytes
derived from mice i.n. administered with OVA plus U-Omp16.
Based on our present results, it seems that the vaccine
formulation, rather than the route of delivery, drives the T
helper profile.
The induction of Th1 and CD8+ T cell responses is highly
desirable, for example, in vaccines targeting either chronic viral
diseases, infections linked to intracellular pathogens, cancer
(therapeutic vaccines) [18] or to modulate allergy diseases
[11,19]. Thus, U-Omp16 would be a suitable adjuvant to be
used in these conditions. Besides, U-Omp16 induces a Th1
immune response similar to the one elicited after CpG co-
administration (Figure S3). Although the TLR9 agonist CpG
seemed quite promising, being a strong Th1 adjuvant, clinical
studies showed that vaccines containing CpG cause a severe
U-Omp16 Is a Th1 Mucosal Adjuvant
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Figure 3.  U-Omp16 administrated in vivo modulates the allergic reaction in a mouse model of food allergy.  (A) Outline of
the experimental design for the mouse model of food allergy in BALB/c mice (n=10/group). (B) Hypersensitivity scores of sensitized
and sensitized/treated mice 30 minutes following the i.g. challenge with CMP (n/group=10). (C) Delayed-type hypersensitivity (DTH)
response to CMP was assayed 3 weeks after the last boost to evaluate the cellular immune response in vivo. Twenty µg of CMP
were injected into one footpad, and saline was injected into the contra lateral footpad, as a negative control. The thickness of both
footpads was measured 48 h later. (D) Cutaneous test in sensitized and treated mice to evaluate the induction of immediate
inflammation. (E) Determination of CMP-specific serum IgG1, IgG2a and IgE after oral CMP sensitization and intranasal treatment.
(H) Treatment with U-Omp16 stimulates the induction of CD4+ CMP-specific T cells that produce IFN-γ. Spleen cells from CMP
sensitized and treated mice were stained with specific anti-CD4 (PE) monoclonal Ab. After permeabilization cells were stained with
anti-IFN-γ (FITC) or isotype control (FITC) monoclonal Abs for intracellular flow cytometry analysis. (G) Splenocytes were collected
24 h after the oral challenge and stimulated in vitro with CMP (350 µg/ml) or casein (200 µg/ml) for 72 h. Levels of IL-5 in culture
supernatants of spleen cells from sensitized and treated mice were determined by ELISA. (I) mRNA expression for cytokines (IL-5
and IFN-γ) and transcription factors (t-bet and gata-3) was quantified 24 h after oral challenge in jejunum segments. Data are
expressed as mean values ±SEM (***P<0.001, **P<0.01, *P<0.05 vs CMP treated group). These results are representative of two
independent experiments with similar results.
doi: 10.1371/journal.pone.0069438.g003
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autoimmune disease, Wegener’s granulomatosis [20]. In
addition toxin based adjuvants such us CT or CTB are
redirected to the olfactory bulb in the CNS when administered
via the nasal route, which has raised concern about adverse
effects at the CNS. For this reason, the search for new
mucosal adjuvants that preferentially induce Th1 responses is
worth the effort. In this work we demonstrated that U-Omp16
nasal delivery does not induce an inflammatory response at the
CNS and most important neither the Ag (OVA) nor this
adjuvant (U-Omp16) reached the CNS after nasal delivery.
Adjuvants are thought to exhibit different modes of action
[21,22]. For example, certain adjuvants are able to convey
long-term presentation of the Ag (depot effect); others induce
an inflammatory response by recruitment of immune cells and
by helping to target them (e.g. by delivering Ags to APCs).
Other adjuvants are capable of enhancing the levels of co-
stimulatory molecules on APCs [23,24]. U-Omp16 has been
shown to activate DCs in vitro and in vivo [16]. In this work we
found that U-Omp16 delivered by the nasal route induces the
production of chemokines and the recruitment of inflammatory
cells at BAL and lungs, which are responsible for the induction
of an inflammatory environment. In this way, i.n administration
of U-Omp16 drives the production of TNF-α and IL-10 in lung
tissues cells 24 h post delivery. Possibly, this early TNF-α
production is involved in the induction of the required
inflammatory context for the initiation of adaptive mucosal
immune responses. Adjuvants should not elicit unacceptable
local reactions, when used in prophylactic and therapeutic
vaccines [25]. IL-10 production -which is involved in anti-
inflammatory processes-, would be an important feature of this
adjuvant because excessive inflammatory responses would be
undesirable. U-Omp16 i.n administration induced an increase
in the number of DCs (CD11c+CD11b- and CD11c+CD11b+)
and monocytes/macrophages (CD11b+CD11c-) in lungs from 2
to 18 h post-inoculation (Figure S4A). As IL-10 and TNF-α are
produced after U-Omp16 stimulation of DCs (BMDCs) and
macrophages (BMDMs) in vitro (Figure S4B), we speculate
that DCs and monocytes are the source of IL-10 and TNF-α in
vivo. Also, U-Omp16 can be internalized by DCs (BMDCs) in
vitro (Figure S4C). In coincidence, i.n delivery of U-Omp16 is
able to induce an increase in the amount of co-delivered Ag
inside lung cells. This ability may result on a reduction of Ag
dose and may help to reduce vaccine costs.
Worth mentioning, histological studies of lungs were
conducted. In coincidence with the recruitment studies a
transient recruitment of immune cells post U-Omp16 nasal
delivery was observed. Remarkably the tissue histology was
not affected. At later time points following administration or
nasal vaccination no cellular infiltrate was observed and the
lung architecture was normal, indicating that no pathological
adverse reaction was induced by U-Omp16, even in the
presence of a memory immune response.
Based on the above-mentioned results, we decided to test U-
Omp16’s adjuvant capability to modulate milk allergy in mice.
Cow’s milk allergy is a global health concern that occurs more
frequently among children than adults. At present, there are no
definitive therapeutic options for food allergy patients. Once a
food allergy is diagnosed, the standard of care includes strict
elimination of the allergen from the diet and ready access to
injectable epinephrine [12,26]. Thus, the induction of allergen-
specific Th1 responses has been proposed as a promising
concept for treatment of Th2-biased hyper-responsiveness.
The intranasal co-administration of U-Omp16 plus CMP during
sensitization decreased clinical signs of hypersensitivity after
oral challenge with the allergen in sensitized mice. In addition,
clinical score values in U-Omp16 administered mice are similar
to LPS-treated group, known as a strong mucosal modulator of
this response. Furthermore, a significant DTH response is
induced in animals i.n. delivered with U-Omp16 or LPS,
indicating that the administration of U-Omp16 during
sensitization as an adjuvant can bypass the mucosal tolerance
mechanisms. Moreover, U-Omp16 administration during
sensitization induces a reduction in allergen-specific serum IgE
and after the cutaneous test no increase in vascular
permeability was observed. These results enabled us to
assume that animals treated with adjuvants during sensitization
have skin mast cells with no detectable specific IgE antibodies
attached to the cell membrane. This situation might be
extended to other mucosal mast cells, and reflects that further
exposure to Ag promotes no hypersensitivity reaction.
To enforce these findings, we found that i.n. delivery of U-
Omp16+CMP during sensitization induces an increase in the
frequency of spleen CD4+ T cells that produce IFN-γ upon in
vitro CMP stimulation. Moreover, U-Omp16 increases ifn-γ and
t-bet gene expression at jejunum that correlates with the Th1
biased immune response induced. These results account for
the ameliorated clinical signs observed after oral allergen
challenge with CMP in animals treated with U-Omp16+CMP
during sensitization. Finally, these findings confirm that the
nasal delivery of U-Omp16 modulates the specific immune
response at the mucosa and systemically.
Of note, U-Omp16 Th1 mucosal adjuvant capabilities have
been demonstrated using C57BL6 mice (OVA model) and
BALB/c mice (CMP model), suggesting that U-Omp16´s activity
is independent on the genetic background, therefore
strengthening and expanding its potential as mucosal adjuvant.
Overall, this work shows that U-Omp16 is a Th1 immune
response inducer that can modulate the Th2 mediated allergic
sensitization and supports U-Omp16’s potential as a broad Th1
mucosal adjuvant for different Ag formulations in line with the
present requirements.
Materials and Methods
Ethics Statement
All experimental protocols of this study were conducted in
strict agreement with international ethical standards for animal
experimentation (Helsinki Declaration and its amendments,
Amsterdam Protocol of welfare and animal protection and
National Institutes of Health, USA NIH, guidelines: Guide for
the Care and Use of Laboratory Animals). All surgeries were
conducted under sodium pentobarbital anesthesia. The
protocols of this study were approved by the Institutional
Committee for the Care and Use of Laboratory Animals from
Institute of Immunology, Genetics and Metabolism
INIGEM-CONICET, University of Buenos Aires (Permit
Number: 102).
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Mice
Female eight week old C57BL/6 and BALB/c mice were
purchased from the School of Animal Science at the National
University of La Plata (La Plata, Argentina). Mice were housed
in appropriate conventional animal care facilities and handled
according to international guidelines required for animal
experiments.
Antigens and adjuvants
OVA grade V (Sigma Aldrich) was dissolved in sterilized
saline solution. The recombinant unlipidated (U-) Omp16 was
expressed and purified as previously described [27,28]. Protein
concentration was determined by the bicinchronic acid assay
(Pierce, Rockford, IL). Lipopolysaccharide (LPS) contamination
was adsorbed with Sepharose-polymyxin B (Sigma-Aldrich, St.
Louis, MO). Endotoxin determination was performed with
Limulus amoebocyte chromogenic assay (LONZA, Argentina).
All U-Omp16 preparations contained less than 0.10 endotoxin
U/mg protein.
In some experiments U-Omp16 was enzymatically digested
to be used as control. For this, U-Omp16 was treated with
proteinase K-agarose from Tricirachium album (Sigma-Aldrich)
for 2 h at 37°C, following the manufacturer’s indications. The
enzyme immobilized in agarose was then centrifuged out (2000
x g, 5 min), and the supernatants were incubated for 1 h at
60°C to inactivate any fraction of soluble enzyme. The
complete digestion of the proteins was checked by SDS-PAGE,
followed by Coomassie blue staining as was described [16].
Preparation of single-cell suspensions
Spleens were aseptically removed and single cell
suspensions were prepared by gently teasing through a sterile
stainless steel screen. To obtain cells from lungs, organs were
removed and digested with 400 U/mL Collagenase Type IV and
50 mg/mL DNase in RPMI 1640 for 30 minutes at 37°C. Cell
suspensions were filtered through a stainless-steel sieve, and
were washed twice in PBS solution.
Bronchoalveolar lavage (BAL)
BAL from mice was obtained as described previously [29]
centrifuged and supernatants were immediately used to detect
cytokines and chemokines. Cell pellets were suspended in
PBS containing 3% bovine serum albumin. Total leucocytes
were counted with a hemocytometer, and the percentages of
different leucocytes were determined using standard
morphological criteria, examining cytospin slides by May-
Grund-Wald and Giemsa staining.
Determination of cytokine and chemokine production in
BAL and lung tissues after U-Omp16 nasal delivery
C57BL/6 mice were i.n. administered with PBS or U-Omp16
(20 µg) and 6, 12, 24 and 48 h after delivery BAL was obtained
from every mouse. The amount of cytokines and chemokines
was evaluated as previously described [29]. The concentration
of TNF-α, IL-10, CCL-2, CCL-3 and CCL-5 in BAL and lung
supernatants was analyzed by ELISA, according to the
manufacturer’s instructions (Pharmingen, San Diego, CA).
Determination of Ag internalization in vivo
OVA Alexa Fluor 647 –OVA (AF647) (Molecular Probes, USA)
was used as Ag. Animals were i.n. administered with OVA(AF647)
(50 µg), plus i) PBS or ii) U-Omp16 (20 µg). After
administration lung cells were obtained at different time points
and washed. The emission of fluorescence was measured in
cell suspensions (1x106 cells/well) using a fluorescence plate
reader (Victor3, PerkinElmer, Waltham, MA).
Immunization and experimental design
C57BL/6 mice were i.n. immunized once a week during 3
weeks with i) OVA (50 µg), ii) OVA (50 µg) plus U-Omp16 (20
µg) or iii) OVA (50 µg) plus U-Omp16 (20 µg previously
digested with proteinase K) in 20 µl per nostril. In some
experiments a group of animals was also immunized with OVA
(50 µg) plus CpG (10 µg) as a control. Blood was obtained on
day 0 and 30 following the first immunization, and three weeks
after the last immunization mice were sacrificed to perform
cellular in vitro experiments.
Determination of the T helper immune responses
Single spleen cell suspensions from immunized and control
mice were cultured in duplicate at 4 x106 cells/ml in RPMI 1640
(Life Technologies BRL, Grand Island, NY) supplemented with
10% FCS (Life Technologies), 1 mM sodium pyruvate, 2 mM L-
glutamine, 100 U penicillin/ml, and 100 mg streptomycin/ml
(complete medium) or with OVA (500 µg/ml) in complete
medium. After 5 days of incubation cell culture supernatants
were collected. IFN-γ, IL-4, IL-10 and IL-17 production was
evaluated by ELISA kits (Pharmingen, San Diego, CA, R&D
Systems, Biocientifica S.A, Argentina).
Intracellular IFN-γ determination
Lung and spleen cells (4x106 cells/well) were cultured in
presence of i) complete medium supplemented with IL-2 (1
U/ml) or ii) OVA (500 µg/ml) plus mitomicin C-treated MO5
cells -B16 melanoma cell line transfected with the ovoalbumin
gene- (25:1) plus IL-2 for 18 h. Thereafter, cells were treated
with 10 µg/ml brefeldin A and were incubated for 6 h. Surface
staining was performed with anti-CD4 (PE-Cy5.5), anti-CD8
(Alexa Fluor 647). Then, cells were permeabilized with saponin
buffer and stained with anti IFN-γ (PE) or with the Isotype (PE)
control. Data acquisition was performed using BD FACSAriaII
and data analysis using FlowJo software.
Histology and histopathology
Lung and brain inflammation was studied at different times
after i.n administration. To assess inflammation at short time
lungs and brain were excised at 12 h (or 24 h) after single
administration, and at longer times (2 weeks) after
administration on days 0 and 7. For this, different formulations
were administered. Groups of mice were administered with (i)
PBS or (ii) U-Omp16 (20 µg). In other experiments, animals
were administered with (i) OVA (50 µg), (ii) OVA (50 µg) + U-
Omp16 (20 µg) or (iii) OVA (50 µg) + CT (1 µg). At the
indicated time post administration lungs and brains were
excised, fixed and preserved in cold sterile para-formaldehide
4%. Then fixed lungs and brain were paraffin embedded.
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Finally, five micrometers thick longitudinal sections of lungs,
and frontal sections of brain, were obtained and stained with
H&E to assess the degree of inflammation or injury in lungs
and brain tissue. The analysis of samples has been made by
an expert pathologist of the National Academy of Medicine
(Buenos Aires, Argentina).
Intranasal administration to study Ag fate in CNS
To study if i.n administration of U-Omp16 induces re-
direction of Ag to CNS OVAFITC labeled (Invitrogen) was used
as model Ag. Animals were i.n administered with (i) PBS, (ii),
OVAFITC (50 µg) or (iii) OVAFITC (50 µg) + U-Omp16 (20 µg).
At different times post administration (2, 12 and 24 h) animals
were sacrificed and brain was excised. Each brain area:
olfactory bulb (OB), forebrain (FB) and posterior brain (PB) was
obtained and suspensions were prepared. Right hemisphere
was used for fluorescence assay. Finally, OVAFITC
fluorescence was measured in a fluorometer (Victor3,
PerkinElmer, Waltham, MA). Also, OVA or U-Omp16 presence
in CNS was assessed by Western blot.
Western Blot Analysis
The OB, FB and PB derived from the left hemisphere, from
different experimental conditions were homogenized using
TOTEX lysis buffer. The protein lysates were quantified by
Bradford method. After that, 100 µg of protein were separated
by SDS/PAGE using 15% acrylamide-bisacrylamide gels and
transferred onto polyvinylidene fluoride membranes. These
were blocked ON at 4°C with TBS/Tween 0.1%. Then
membranes were washed with TBS/Tween 0.05% and
incubated with primary antibody anti-OVA (1:2000) and anti-
Omp16 (1:4000) ON at 4°C. Membranes were washed with
TBS/Tween 0.05%, incubated for 1 h and 30 minutes with
secondary antibody horseradishperoxidase-conjugated
secondary antibodies (1:2000 and 1:5000 respectively),
washed in TBS/Tween 0.05% and then developed with ECL.
To confirm equal protein loading of all lanes, the same blots
were reprobed with an anti-actin antibody.
Recruitment of DCs and monocytes
C57BL/6 mice were i.n administered once with (i) OVA (50
µg), (ii) OVA (50 µg) + U-Omp16 (20 µg) or (iii) OVA (50 µg) +
CT (1 µg). At different times after administration (2 and 18 h)
mice were sacrificed and heart perfused with sterile saline
solution. After that, lungs were excised and cell suspensions of
the organ were obtained. Cells (6x106) were stained with
monoclonal Abs anti-CD11c and CD11b and were analyzed by
flow cytometry (FACsAriaII, BD Bioscience).
BMDCs and BMDMs
DCs and macrophages were generated from bone marrow
(BM) mononuclear cells from wild-type C57BL/6 mice. Briefly,
femurs and tibiae were collected from mice with 6–12 wk old.
After removing bone adjacent muscles, marrow cells were
extracted by flushing RPMI 1640 medium through the bone
interior. Bone marrow cells were then suspended on DC culture
medium (RPMI 1640 medium, 10% heat-inactivated fetal/
bovine serum, 1 mM sodium pyruvate, 2 mM L-glutamine, 100
U penicillin/ml, and 100 mg streptomycin/ml, 20 ng/ml GM-
CSF) or macrophages culture medium (RPMI 1640 medium,
10% heat-inactivated fetal/bovine serum, 1 mM sodium
pyruvate, 2 mM L-glutamine, 100 U penicillin/ml, and 100 mg
streptomycin/ml, 20 ng/ml M-CSF), and plated on 6 wells plate
(1,5 × 106 cells/2 ml culture medium). On days 3 and 5, the
cells were refed. On day 8, cells were harvested and
expression of DCs (CD11c+, MHC class II (MHCII)low or
monocytes (CD11b+) markers were analyzed by flow
cytometry.
BMDCs and BMDMs stimulation and U-Omp16
internalization in vitro
To study if DCs and monocyte/macrophages were implicated
in the production of pro- and anti-inflammatory cytokines,
BMDCs and BMDMs (1x106 cells) were incubated in vitro with
(i) complete medium or (ii) U-Omp16 (20 or 100 µg/ml) for 20 h.
After incubation, supernatants were harvested and
concentration of TNF-α and IL-10 was determined by ELISA.
In other experiment internalization of U-Omp16 was
assessed. In this assay U-Omp16 FITC labeled (Invitrogen)
was used to determine internalization. BMDCs (1x106 cells)
were incubated for 15 and 30 minutes in vitro with: (i) complete
medium, (ii) U-Omp16 (20 µg/ml) or (iii) U-Omp16 (100 µg/ml).
After incubation cells were washed and internalization was
measured by flow cytometry (FACsAriaII, BD Bioscience).
Intranasal immunomodulation with U-Omp16 in a Cow´
s Milk Protein food allergy mouse model
BALB/c mice were rendered allergic to CMP as previously
described [30]. Briefly, mice received 6 weekly intragastric (i.g.)
doses of 20 mg of CMP administered as homogenized
commercial non-fat dry milk, plus 10 µg of cholera toxin (CT)
(Sigma Aldrich, USA) (sensitized mice). Age-matched naïve
mice received 6 weekly i.g. doses of 20 mg CMP without CT
(sham control). Mice were fasted for 2 h before sensitization,
and 3% sodium bicarbonate solution was given to reduce
gastric acidity 30 min before the immunization. Ten days after
the final boost mice were i.g. challenged with 20 mg CMP.
Blood samples were collected during the sensitization phase
and sera were stored at -20 °C until used. To modulate the
allergic sensitization, mice received twice a week during 4
weeks through intranasal route 4 µg CMP plus 100 µg U-
Omp16 (Treat U-Omp16), 4 µg CMP plus 20 µg of LPS (Treat
LPS) as a positive treatment control or 4 µg CMP as negative
treatment control (Treat CMP). Twenty-four hours following the
oral challenge animals were sacrificed and spleens and
jejunum were collected. The experimental design is depicted in
Figure 3A.
In vivo evaluation of the allergic state
Assessment of clinical signs.  Symptoms were observed
between 30 and 60 min after the oral challenge in a blinded
fashion by 2 independent investigators. Clinical scores were
assigned according to the following range: 0 = no symptoms; 1
= scratching and rubbing around the nose and head; 2 =
puffiness around the eyes and mouth, diarrhea, pilar erecti,
reduced activity, and/or decreased activity with increase
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respiratory rate; 3 = wheezing, labored respiration, cyanosis
around the mouth and the tail; 4 = no activity after prodding, or
tremor and convulsion; and 5 = death.
Cutaneous test.  Mice were shaved on both flanks and
injected intradermically with 200 µg of CMP in 50 µl of sterile
saline in one flank, and saline alone in the other flank as
negative control. Mice were also injected intravenously (tail
vein) with 100 µl of 0.1% Evans blue dye (Anedra, Argentina).
The presence of blue color in the skin 30 min following the
injection was considered a positive reaction.
DTH test.  Three weeks after the last boost the delayed-type
hypersensitivity (DTH) response was measured by determining
footpad swelling after subcutaneous injection of 20 µg of CMP
in 20 µl PBS into one hind footpad. As a negative control saline
was similarly injected into the contralateral footpad. Footpad
swelling was measured 48 h post injection with a digital
micrometer with a minimum increment of 0.01 mm.
In vitro evaluation of allergic disease
Serum CMP-specific IgE, IgG1 and IgG2a detection.  For
the evaluation of specific IgE antibodies against CMP serum
samples were tested by EAST as previously described [31].
Serum CMP-specific IgG1 and IgG2a antibodies were
measured by ELISA as described [30].
Cytokine response of splenocytes to CMP
stimulation.  Twenty-four hours after the oral challenge mice
were killed and spleens were aseptically removed. Splenocytes
were cultured at a concentration of 4 x106 cells/well for 72 h at
37 °C in the presence of complete medium or in medium
containing CMP (0.35 mg/ml), bovine casein (0.20 mg/ml), or
ConA (5 µg/ml) as a positive control. Supernatants were
harvested and assayed for IL-5 by ELISA commercial kit
(Invitrogen, Invitrogen Corporation, USA).
Mucosal gene expression.  Jejunum was aseptically
removed from mice killed by cervical dislocation 24 h following
oral challenge, and mRNA was isolated using illustra RNAspin
mini isolation kit according to manufacturer’s specifications (GE
Healthcare, Germany). Peyer’s patches were discarded prior to
tissue processing. The amount of the extracted RNA was
determined by UV absorption and the optical density ratio of
OD280nm/OD260nm was used as a purity measure.
Complementary DNA (cDNA) was obtained by RT-PCR
(Invitrogen, Life technologies, USA) and mRNA expression was
determined by real-time quantitative PCR. The experimental
procedure was performed on ABI prims sequence detection
system using SYBRGreen fluorescence (BioRad, USA). β-actin
was used to standardize the total amount of cDNA, and the fold
change in mRNA expression was defined as the ratio of the
normalized values corresponding to the sensitized mouse to
that of control mouse. Genes of interest were IFN-γ, IL-5,
gata-3 and t-bet.
Statistical analysis
All statistical analyses and plotting were carried out using
GraphPad Prism 5 software. T test was conducted if 2
experimental groups were performed, whereas when more
than 2 groups were conducted, the significance of the
difference was determined using ANOVA test. When data did
not fit a Gaussian distribution, a logarithmical transformation
was done to achieve a normal distribution. A P value <0.05 was
considered as statistically significant.
Supporting Information
Figure S1.  Intranasal administration of U-Omp16 does not
cause histological changes in lung tissues.  Longitudinal
sections of the lungs from mice were obtained at 12 h or 2
weeks after i.n administration of (i) PBS or (ii) U-Omp16 (20
µg). Lung histology (10X and 40X right panels) at 12 h after a
single administration (A) and at 2 weeks (B) after
administration on days 0 and 7 is shown. Other mice were i.n
administered once or in two occasions (day 0 and 7) with (i)
OVA (50 µg), (ii) OVA (50 µg) + U-Omp16 (20 µg) or (iii) OVA
(50 µg) + CT (1 µg). At 12 or 24 h (C or D) after a single
administration and (E) 2 weeks after 2 doses, lungs were
excised for histological study (n/group=5). All images are (10X)
and magnifications (40X) are shown in each picture. At the
indicated time post administration lungs were excised and fixed
in cold sterile para-formaldehide 4%. Sections of lungs were
obtained and stained with H&E to assess the degree of
inflammation or damage in lung structure. Representative
pictures from each group are shown.
(TIF)
Figure S2.  Intranasal co-administration with U-Omp16
does not re-direct the antigen to CNS.  Western blots
analysis of OVA and U-Omp16 in different brain areas. (A)
Protein lysates of olfactory bulb (OB), forebrain (FB) and
posterior brain (PB) were obtained from animals i.n
administered once with (i) PBS (control), (ii) OVAFITC (50 µg)
or (iii) OVAFITC (50 µg) +U-Omp16 (20 µg) at different time
points after administration (2, 12 and 24 h). Protein amount in
the lysates was quantified by Bradford method and for Western
blot experiments 100 µg of total protein were used per lane. (B)
Western blot analysis of OVA in lysates of OB, FB and PB from
mice that were i.n administered with the different formulations
(n/group=5). (C) Suspensions of the different brain areas were
obtained and OVAFITC presence was determined in a
fluorometer (Victor3, PerkinElmer, Waltham, MA). Data in each
row represents the mean of µg OVAFITC/µg of brain area (OB,
FB or PB) ±SEM in each analyzed time. Results are
representative of two independent experiments. (D) Western
blot analysis of U-Omp16 in protein lysates of OB, FB and PB
from mice that were i.n administered with the different
formulations (n/group=5). (E) U-Omp16 does not induce
inflammation in olfactory bulb. Animals were i.n.
administered once, or on days 0 and 7 with (i) PBS or (ii) U-
Omp16 (20 µg) and 12 h or 2 weeks respectively, brains were
excised and fixed in cold sterile para-formaldehide 4%.
Sections of the OB were obtained and stained with H&E to
assess the degree of inflammation. Histology of the OB from
mice representative from each group (10X) is shown.
(TIF)
Figure S3.  Immunization with U-Omp16 induces a Th1
immune response against OVA similar to the one induced
U-Omp16 Is a Th1 Mucosal Adjuvant
PLOS ONE | www.plosone.org 11 July 2013 | Volume 8 | Issue 7 | e69438
by CpG.  Mice were immunized by the nasal route with OVA
(50 µg) plus i) PBS, ii) U-Omp16 (20 µg) previously digested
with proteinase K (U-Omp16PK), iii) U-Omp16 (20 µg) or iv)
CpG (10 µg) on days 0, 7 and 14. Three weeks after last
immunization animals were sacrificed and spleen cells were
stimulated in vitro with OVA 500 µg/ml or complete medium.
Culture supernatants were harvested 5 days after stimulation
and cytokine concentration of (A) IFN-γ, (B) IL-4 and (C) IL-10
(pg/ml) were determined by ELISA. Data represent the mean
±SEM from each group of five mice; (**P<0.01, *P<0.05 vs
OVA and OVA+U-Omp16PK groups). These results are
representative of two independent experiments with similar
results.
(TIF)
Figure S4.  Nasal administration of U-Omp16 induces
recruitment of DCs and monocytes/macrophages in lung
tissue.  Animals were i.n. administered once with i) OVA, ii)
OVA+U-Omp16 or iii) OVA+CT. At different times (2 and 18 h)
post administration lungs were excised and cellular
suspensions were obtained. Cells (6x106) were stained with
specific Abs anti-CD11c, anti-CD11b for flow cytometry
analysis (A). Data represent the number of cells/lung from
administered animals ±SEM (**P<0.01 and *P<0.05 vs OVA
group). U-Omp16 induces the production of TNF-α and
IL-10 by BMDCs and BMDMs in vitro. BMDCs and BMDMs
were stimulated for 20 h with different doses of U-Omp16 (20
or 100 µg/ml) or complete medium (control). After in vitro
stimulation supernatants were harvested and concentrations
(pg/ml) of TNF-α and IL-10 were determined (B). Data
represents means (pg/ml) of duplicate determinations ±SEM
(***P<0.001 and **P<0.01 vs medium). U-Omp16 is
internalized by DCs in vitro. BMDCs (1x106) were incubated
for 15 or 30 minutes with U-Omp16FITC labeled (20 or 100
µg/ml) or complete medium (control). After incubation, cells
were washed and U-Omp16 fate was determined by flow
cytometry (C). Data represents the median fluorescence
intensity (MFI) ±SEM (***P<0.001 and **P<0.01 vs control).
(TIF)
Author Contributions
Conceived and designed the experiments: AEI PS GHD JC.
Performed the experiments: AEI PS LMC GSR MVD LP.
Analyzed the data: AEI PS GHD JC GHG SCO. Contributed
reagents/materials/analysis tools: AEI KAP PS GHG CAF JC.
Wrote the manuscript: AEI JC.
References
1. Lawson LB, Norton EB, Clements JD (2011) Defending the mucosa:
adjuvant and carrier formulations for mucosal immunity. Curr Opin
Immunol 23: 414-420. doi:10.1016/j.coi.2011.03.009. PubMed:
21511452.
2. Freytag LC, Clements JD (2005) Mucosal adjuvants. Vaccine 23:
1804-1813. doi:10.1016/j.vaccine.2004.11.010. PubMed: 15734046.
3. Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in
adjuvants for vaccine development. Trends Immunol 30: 23-32. doi:
10.1016/j.it.2008.09.006. PubMed: 19059004.
4. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT et al. (2004) Use of
the inactivated intranasal influenza vaccine and the risk of Bell’s palsy
in Switzerland. N Engl J Med 350: 896-903. doi:10.1056/
NEJMoa030595. PubMed: 14985487.
5. Steinhagen F, Kinjo T, Bode C, Klinman DM (2011) TLR-based
immune adjuvants. Vaccine 29: 3341-3355. doi:10.1016/j.vaccine.
2010.08.002. PubMed: 20713100.
6. Carozzi S, Salit M, Cantaluppi A, Nasini MG, Barocci S et al. (1989)
Effect of monophosphoryl lipid A on the in vitro function of peritoneal
leukocytes from uremic patients on continuous ambulatory peritoneal
dialysis. J Clin Microbiol 27: 1748-1753. PubMed: 2504774.
7. Henricson BE, Manthey CL, Perera PY, Hamilton TA, Vogel SN (1993)
Dissociation of lipopolysaccharide (LPS)-inducible gene expression in
murine macrophages pretreated with smooth LPS versus
monophosphoryl lipid A. Infect Immun 61: 2325-2333. PubMed:
8388859.
8. Myers KR, Beining P, Betts M, Snippe H, Inman J et al. (1995)
Monophosphoryl lipid A behaves as a T-cell-independent type 1 carrier
for hapten-specific antibody responses in mice. Infect Immun 63:
168-174. PubMed: 7806354.
9. Hessel EM, Chu M, Lizcano JO, Chang B, Herman N et al. (2005)
Immunostimulatory oligonucleotides block allergic airway inflammation
by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J
Exp Med 202: 1563-1573. doi:10.1084/jem.20050631. PubMed:
16314434.
10. Johansen P, Senti G, Martinez Gomez JM, Storni T, von Beust BR et
al. (2005) Toll-like receptor ligands as adjuvants in allergen-specific
immunotherapy. Clin Exp Allergy 35: 1591-1598. doi:10.1111/j.
1365-2222.2005.02384.x. PubMed: 16393325.
11. Crameri R, Rhyner C (2006) Novel vaccines and adjuvants for allergen-
specific immunotherapy. Curr Opin Immunol 18: 761-768. doi:10.1016/
j.coi.2006.09.001. PubMed: 17010585.
12. Sicherer SH, Teuber S (2004) Current approach to the diagnosis and
management of adverse reactions to foods. J Allergy Clin Immunol 114:
1146-1150. doi:10.1016/j.jaci.2004.07.034. PubMed: 15536423.
13. Sampson HA, Anderson JA (2000) Summary and recommendations:
Classification of gastrointestinal manifestations due to immunologic
reactions to foods in infants and young children. J Pediatr
Gastroenterol Nutr 30 Suppl: S87-S94. doi:
10.1097/00005176-200001001-00013. PubMed: 10634304.
14. Host A (1994) Cow’s milk protein allergy and intolerance in infancy.
Some clinical, epidemiological and immunological aspects. Pediatr
Allergy Immunol 5: 1-36. doi:10.1111/j.1399-3038.1994.tb00210.x.
15. Cianferoni A, Muraro A (2012) Food-induced anaphylaxis. Immunol
Allergy Clin North AM 32: 165-195. doi:10.1016/j.iac.2011.10.002.
PubMed: 22244239.
16. Pasquevich KA, García Samartino C, Coria LM, Estein SM, Zwerdling
A et al. (2010) The protein moiety of Brucella abortus outer membrane
protein 16 is a new bacterial pathogen-associated molecular pattern
that activates dendritic cells in vivo, induces a Th1 immune response,
and is a promising self-adjuvanting vaccine against systemic and oral
acquired brucellosis. J Immunol 184: 5200-5212. doi:10.4049/jimmunol.
0902209. PubMed: 20351187.
17. Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA (2009) Intranasal
immunization promotes th17 immune responses. J Immunol 183:
6933-6938. doi:10.4049/jimmunol.0901144. PubMed: 19890060.
18. Seder RA, Hill AV (2000) Vaccines against intracellular infections
requiring cellular immunity. Nature 406: 793-798. doi:
10.1038/35021239. PubMed: 10963610.
19. De Souza Rebouças J, Esparza I, Ferrer M, Sanz ML, Irache JM et al.
(2012) Nanoparticulate adjuvants and delivery systems for allergen
immunotherapy. J Biomed Biotechnol, 2012: 2012: 474605. PubMed:
22496608
20. Hurtado PR, Jeffs L, Nitschke J, Patel M, Sarvestani G et al. (2008)
CpG oligodeoxynucleotide stimulates production of anti-neutrophil
cytoplasmic antibodies in ANCA associated vasculitis. BMC Immunol 9:
34. doi:10.1186/1471-2172-9-34. PubMed: 18625057.
21. Cox JC, Coulter AR (1997) Adjuvants--a classification and review of
their modes of action. Vaccine 15: 248-256. doi:10.1016/
S0264-410X(96)00183-1. PubMed: 9139482.
22. Cox E, Verdonck F, Vanrompay D, Goddeeris B (2006) Adjuvants
modulating mucosal immune responses or directing systemic
responses towards the mucosa. Vet Res 37: 511-539. doi:10.1051/
vetres:2006014. PubMed: 16611561.
U-Omp16 Is a Th1 Mucosal Adjuvant
PLOS ONE | www.plosone.org 12 July 2013 | Volume 8 | Issue 7 | e69438
23. Schijns VE (2000) Immunological concepts of vaccine adjuvant activity.
Curr Opin Immunol 12: 456-463. doi:10.1016/S0952-7915(00)00120-5.
PubMed: 10899018.
24. Pashine A, Valiante NM, Ulmer JB (2005) Targeting the innate immune
response with improved vaccine adjuvants. Nat Med 11: S63-S68. doi:
10.1038/nm1210. PubMed: 15812492.
25. Sesardic D (2006) Regulatory considerations on new adjuvants and
delivery systems. Vaccine 24 Suppl 2: S2-86-87. PubMed: 16823940.
26. Sampson HA (1999) Food allergy. Part 1: immunopathogenesis and
clinical disorders. J Allergy Clin Immunol 103: 717-728. doi:10.1016/
S0091-6749(99)70411-2. PubMed: 10329801.
27. Giambartolomei GH, Zwerdling A, Cassataro J, Bruno L, Fossati CA et
al. (2004) Lipoproteins, not lipopolysaccharide, are the key mediators of
the proinflammatory response elicited by heat-killed Brucella abortus. J
Immunol 173: 4635-4642. PubMed: 15383598.
28. Pasquevich KA, Estein SM, García Samartino C, Zwerdling A, Coria
LM et al. (2009) Immunization with recombinant Brucella species outer
membrane protein Omp16 or Omp19 in adjuvant induces specific
CD4+ and CD8+ T cells as well as systemic and oral protection against
Brucella abortus infection. Infect Immun 77: 436-445. doi:10.1128/IAI.
01151-08. PubMed: 18981242.
29. Garcia TC, Fonseca CT, Pacifico LG, Duraes Fdo V, Marinho FA et al.
(2008) Peptides containing T cell epitopes, derived from Sm14, but not
from paramyosin, induce a Th1 type of immune response, reduction in
liver pathology and partial protection against Schistosoma mansoni
infection in mice. Acta Trop 106: 162-167. doi:10.1016/j.actatropica.
2008.03.003. PubMed: 18423420.
30. Smaldini P, Curciarello R, Candreva A, Rey MA, Fossati CA et al.
(2012) In vivo Evidence of Cross-Reactivity between Cow’s Milk and
Soybean Proteins in a Mouse Model of Food Allergy. Int Arch Allergy
Immunol 158: 335-346. doi:10.1159/000333562. PubMed: 22472742.
31. Ceska M, Lundkvist U (1972) A new and simple radioimmunoassay
method for the determination of IgE. Immunochemistry 9: 1021-1030.
doi:10.1016/0019-2791(72)90112-7. PubMed: 4538963.
U-Omp16 Is a Th1 Mucosal Adjuvant
PLOS ONE | www.plosone.org 13 July 2013 | Volume 8 | Issue 7 | e69438
